Navigation Links
InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting

CDC), an estimated 3.9 million Americans (1.8%) have been infected with HCV, of whom 2.7 million are chronically infected. It is estimated that there are 170 million people worldwide afflicted with this disease. While currently available therapies can cure many patients, there is considerable need for the development of novel therapeutic approaches. The HCV NS3/4 protease is an attractive drug target because of its potential involvement in viral replication and suppressive effects on host response to viral infection. Inhibitors of the HCV protease, such as ITMN-191, represent a promising new class of drugs for HCV.

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 in Phase 1a, a second-generation HCV protease inhibitor program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Except for the historical information contained herein, this press release contains certain forward-looking statements that involve risks and uncertainties, including without limitation the statements related to the progress, future patient enrollment in and timing of our clinical trials and announcements of results thereof. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof
'"/>




Page: 1 2 3 4

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: InterMune Presents Research ITMN Hepatitis EASL Annual Meeting
(Date:9/2/2014)... , Sept. 2, 2014  For over a decade ... no link between vaccines and autism. But at least for ... In a statement , William Thompson , ... information" linking the MMR vaccine to an increased risk of ... of the same data suggests that African American males have ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014 /PRNewswire-iReach/ -- ... just recognized as one of the fastest growing ... past few years, the company has undergone significant ... research, late phase global clinical development, anti-viral and ... 2 years, WCCT Global has successfully participated in ...
(Date:9/1/2014)... Sept. 1, 2014 Reportlinker.com announces that ... its catalogue:  Drug Discovery Technologies - A ... http://www.reportlinker.com/p02349116/Drug-Discovery-Technologies---A-Global-Market-Overview.html The development of new ... requires extensive expenditure, in addition to consuming a ... a new drug involves the utilizing high-throughput screening ...
Breaking Medicine Technology:CDC vaccine scientist admits wrongdoing. 2CDC vaccine scientist admits wrongdoing. 3Contract Research Organization WCCT Global Celebrates Being Named as One of the Fastest Growing Companies in America 2Drug Discovery Technologies - A Global Market Overview 2Drug Discovery Technologies - A Global Market Overview 3Drug Discovery Technologies - A Global Market Overview 4Drug Discovery Technologies - A Global Market Overview 5Drug Discovery Technologies - A Global Market Overview 6Drug Discovery Technologies - A Global Market Overview 7Drug Discovery Technologies - A Global Market Overview 8Drug Discovery Technologies - A Global Market Overview 9Drug Discovery Technologies - A Global Market Overview 10Drug Discovery Technologies - A Global Market Overview 11Drug Discovery Technologies - A Global Market Overview 12Drug Discovery Technologies - A Global Market Overview 13Drug Discovery Technologies - A Global Market Overview 14
... Dec. 21, 2011  Shareholders of Medco Health Solutions, Inc. (NYSE: ... Express Scripts. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO ) ... vote present in person or by proxy at a special ... Merger dated July 20, 2011 by a margin of 99 ...
... 2011 Actavis Group, the international generic pharmaceuticals company, today ... a binding letter of intent (LOI) with QRxPharma Limited (ASX: ... United States.  Under the terms of the ... IR, a patented 3:2 ratio fixed dose combination of morphine ...
Cached Medicine Technology:Medco Shareholders Approve Merger With Express Scripts 2Actavis to Launch Novel Pain Medication in the US 2Actavis to Launch Novel Pain Medication in the US 3
(Date:9/2/2014)... N.J. (PRWEB) September 02, 2014 ... technologies and development solutions for drugs, biologics and ... of its strategic partner, Eli Lilly’s growth, it ... packaging lines at its Philadelphia Clinical Supply Center ... syringe packaging capabilities in its clinical supply facility ...
(Date:9/2/2014)... The performance of the Lotteries ... years. Industry revenue is estimated to grow at a ... through 2014-15, following stabilised growth over the past three ... alternate forms of gambling. Horse and sports betting, poker ... all become increasingly popular over the past five years, ...
(Date:9/2/2014)... Based on new studies, concerns ... kidney and spleen surgeries, have continued to mount. ... patients. , An article in the "Public ... Titilope Oduyebo and Bradley J. Quade called, "Peritoneal ... on Nov 26, 2012 defines a morcellator ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- When it comes to excess ... equal, a new study finds. The research found that ... person,s odds for high blood pressure more than overall body ... of high blood pressure. But it wasn,t clear how the ... to researchers at University of Texas Southwestern Medical Center in ...
(Date:9/2/2014)... York (PRWEB) September 02, 2014 ... announces that Class Counsel has filed an application ... awards in the class action litigation brought over ... LLP, the Court-Appointed Class Counsel in this litigation ... Bernstein, LLP; Audet & Partners, LLP; Levin Fishbein, ...
Breaking Medicine News(10 mins):Health News:Catalent Supports Eli Lilly's Growing Global Clinical Trials Needs with New Investment in Automated Packaging Solutions 2Health News:Lotteries in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Lotteries in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:New York Law Firm Discusses Allegedly Dangerous Surgical Morcellator Devices And Cancer Risk 2Health News:New York Law Firm Discusses Allegedly Dangerous Surgical Morcellator Devices And Cancer Risk 3Health News:'Spare Tire' May Be Especially Bad for Your Blood Pressure 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 3
... a brain cancer death sentence. It is the most lethal ... are diagnosed with GBM annually in the U.S., half ... within 3 years. The treatments include highly invasive surgeries to ... dose, both leading to a very low quality of life. ...
... conducted by the University of Michigan’s researchers has revealed that those ... unsafe are likely to put on weight. As many as 16% ... in the US are reported to be overweight, while in the ... tripled since the early 1990s. ,The researchers, led ...
... one more reason to raise a toast- a formula for ... // can pep-up your spirits and relish the ... University, and author of the formula for Marks & Spencer, ... open a champagne bottle. According to smith, P = T/4.5 ...
... difficult acrobatic stunts and are paying the price with a ... ,Cheerleaders catapult in the air, climb human ... the ground. They also make it to the emergency room. ... Pediatrics estimates that 208,800 young people aged 5 to 18 ...
... that is mainly present in pain relievers. Recently there is ... // clinicians complaining about over dosage of Acetaminophen. ... 50% of these cases are unintentional. Drugs like Tylenol, Benadryl, ... as one of the main composition in them. ...
... smokers or those who have been smoking in the past have ... tomography (CT scan) to detect // lung cancer if any, ... effective treatment and thereby improve the prognosis. ,The ... family history of the dreadful disease. For those of you ...
Cached Medicine News:Health News:Radiology advance points way to non-invasive brain cancer treatment 2Health News:Surroundings Have An Effect On Weight 2Health News:Cheerleaders run high risk of injury-US study 2Health News:Painkillers Lead To Liver Failure 2Health News:CT Scan A Must For Smokers With Family History Of Lung Cancer 2
... navigation for Spine is ... integrate C-arm fluoroscopy with ... 3500 - spine Multi-application ... for ENT, cranial and ...
The ZEPHIR Anterior Cervical Plate System is the lowest profile plate clinically available....
... Mx8000 is a family of multislice CT ... version, Mx8000 also is available in an ... the same friendly user interface, advanced applications ... Both Dual and Quad systems can be ...
... 16 is Philips premium 16-slice CT scanner. ... to automatically delivering high quality, advanced results, the ... a platform that has been the most popular ... comprehensive organ assessment literally within seconds, and with ...
Medicine Products: